Water Island Capital LLC purchased a new position in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 150,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,693,000. Water Island Capital LLC owned approximately 0.32% of Sucampo Pharmaceuticals at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Kennedy Capital Management Inc. purchased a new position in Sucampo Pharmaceuticals in the 4th quarter worth about $6,346,000. OppenheimerFunds Inc. boosted its position in Sucampo Pharmaceuticals by 443.5% during the 4th quarter. OppenheimerFunds Inc. now owns 77,292 shares of the biopharmaceutical company’s stock worth $1,387,000 after acquiring an additional 63,072 shares during the period. FDx Advisors Inc. acquired a new stake in Sucampo Pharmaceuticals during the 4th quarter worth about $180,000. Ontario Teachers Pension Plan Board acquired a new stake in Sucampo Pharmaceuticals during the 4th quarter worth about $218,000. Finally, Virtu Financial LLC acquired a new stake in Sucampo Pharmaceuticals during the 4th quarter worth about $1,056,000. 67.09% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have commented on SCMP. UBS lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research report on Friday, January 5th. B. Riley lowered Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price objective for the company. in a research report on Tuesday, December 26th. BidaskClub lowered Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. ValuEngine upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 9th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.73.
Shares of Sucampo Pharmaceuticals, Inc. (SCMP) opened at $18.00 on Friday. The stock has a market capitalization of $839.46, a PE ratio of -5.37, a PEG ratio of 5.06 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. Sucampo Pharmaceuticals, Inc. has a 1-year low of $9.30 and a 1-year high of $18.75.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2018/03/17/150000-shares-in-sucampo-pharmaceuticals-inc-scmp-acquired-by-water-island-capital-llc.html.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.